Building Kidney Exchange Programmes in Europe – An Overview of Exchange Practice and Activities


1 Institute of Economics, Hungarian Academy of Sciences, Budapest, Hungary
2 Dutch Transplantation Foundation, Leiden, The Netherlands
3 Department of Economics, Lund University, Lund, Sweden
4 School of Science and Engineering, Reykjavik University, Reykjavik, Iceland
5 Transplant Center, L. Pasteur's University Hospital, Košice, Slovakia
6 Nephrology Department, Laikon Hospital, Athens, Greece
7 Instituto Portugues do Sangue e da Transplantacao, Lisbon, Portugal
8 Medical University Vienna, Vienna, Austria
9 National Health Service Blood and Transplant, Bristol, United Kingdom

10 Institute of Mathematics, P.J. Safarik University, Košice, Slovakia

11 Italian National Transplant Centre (CNT), Rome, Italy

12 Institute for Clinical and Experimental Medicine, Prague, Czech Republic

13 Geneva University Hospitals, Geneva, Switzerland

14 Agence de la Biomedecine, Saint-Denis, France

15 Medical University of Warsaw, Warsaw, Poland

16 KU Leuven, Leuven, Belgium

17 United Network for Organ Sharing (UNOS), Richmond, USA

18 School of Computing Sciences, University of Glasgow, Glasgow, United Kingdom

19 Hellenic Transplant Organization, Athens, Greece

20 Department of Political and Economic Studies, University of Helsinki, Helsinki, Finland

21 HEC Management School, Université de Liege, Liege, Belgium

22 Organización Nacional de Trasplantes (ONT), Madrid, Spain

23 Department of Computer Science, University College Cork, Cork, Ireland

24 Prince Mohammad Bin Salman College, King Abdullah Economic City, Kingdom of Saudi Arabia

*contributed equally
Authorship

PB, BH and JvK organised the survey and research. The 2 first authors have contributed equally as regards design, analyses of the study and writing the manuscript as the chair and vice-chair of Working Group 1 of the ENCKEP COST Action. DM, JvK contributed significantly in writing the paper while JvK was chair of the COST Action. LB and RJ contributed to the questionnaire design. All the remaining authors have provided information in the questionnaires on their countries of origin, also including LB, BH, AH and RJ. Finally, TA, CB, GB, KC, PDC, JF, BH, KH, RJ, RK, RL, M-AM, GM, BS and MV gave presentations about their national KEps, and everyone participated in the discussions at the ENCKEP workshops.

Disclosure

The authors declare no conflicts of interest.

Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abbreviations

COST – Cooperation on Science and Technology

ENCKEP – European Network for Collaboration on Kidney Exchange Programmes

KEP – kidney exchange programme

ESRD – end-stage renal disease

LDKT – living donor kidney transplantation

HLA – Human leukocyte antigen

UKLKSS – UK Living Kidney Sharing Schemes

NHSBT – NHS Blood and Transplant

H&I – histocompatibility and immunogenetics

ONT – Organización Nacional de Transplantes

IKEM – Institute for Clinical and Experimental Medicine

ABOi – ABO incompatible

HLAi – HLA incompatible

CNT – Italian National Transplant Centre

MFI – Mean Fluorescence Intensity

IPST – Instituto Português do Sangue e da Transplantação

STEP – ScandiaTransplant Kidney Exchange Program

UNOS – United Network for Organ Sharing
Abstract

Background: Considerable differences exist among the living donor Kidney Exchange Programmes (KEPs) that are in use and being built in Europe, contributing to a variation in the number of living donor transplants [6]. Efforts of European KEPs to exchange (best) practices and share approaches to address challenges have, however, been limited.

Methods: Experts from 23 European countries, collaborating on the ENCKEP COST Action, developed a questionnaire to collect detailed information on the functioning of all existing KEPs in Europe, as well as their opportunities and challenges. Following a comparative analysis, results were synthesised and interpreted by the same experts.

Results: The practices, opportunities and challenges reported by 17 European countries reveal that some of the 10 operating programmes are mature, while others are in earlier stages of development. Over 1300 transplants were performed through existing KEPs up to the end of 2016, providing approximately 8% of their countries’ living kidney donations in 2015. All countries report challenges to either initiating KEPs or increasing volumes. Some challenges are shared, whilst others differ because of differences in context (eg, country size, effectiveness of deceased donor programme) and ethical and legal considerations (eg, regarding living donation as such, nonrelated donors, and altruistic donation). Transnational initiatives have started in Central Europe, Scandinavia, and Southern Europe.

Conclusions: Exchange of best practices and shared advancement of national programmes to address existing challenges, aided by transnational exchanges, may substantially improve access to the most (cost) effective treatment for the increasing number of patients suffering from kidney disease.
Introduction

For patients suffering from end-stage renal disease (ESRD), living donor kidney transplantation (LDKT) is more (cost) effective than deceased donor transplantation and dialysis ([1], [2], [3]). In particular, it yields better patient and graft survival [4]. Over the past 2 decades, many countries have developed or intensified LDKT programmes, often to supplement shortages in supply of donor organs for deceased donor programmes. Other countries however, still largely rely on deceased donor programmes. As of 2015, LDKT accumulates to 40% of approximately 80 000 kidney transplantations worldwide [5].

The differences in adoption and implementation of LDKT programmes in Europe result in a variation from 0 to 33.2 in the number of living donor transplants per million inhabitants per year [6]. This variation indicates that initiating and advancing KEPs can bring the benefit of treating more European ESRD patients, and/or treating them more (cost)-effectively.

Originally, LDKT was only feasible for patients with intended living donors of compatible blood group and HLA type. Depending on the country, 40% or more of recipients are incompatible with their intended donors [5]. Kidney Exchange Programmes (KEPs) enable transplantation for recipients who are blood- and/or HLA incompatible with their initially intended donors. These incompatible pairs can join a larger pool of recipient-donor pairs, within which recipients may exchange donors. The KEP management identifies matching donors for the recipients and arranges the transplantations to take place. Many countries across the globe, and specifically in Europe, are establishing KEPs and facing a variety of common challenges. Additionally, some of the countries with existing KEPs appear to face challenges in increasing transplant numbers, despite considerable demand. Hence, there appears to be much to gain from collaboration and mutual learning.
The COST (Cooperation on Science and Technology) Association funds such a collaboration and mutual-learning project, namely the ENCKEP COST Action (European Network for Collaboration on Kidney Exchange Programmes [7]). The COST Association is a European framework whose actions are open to all 36 member-states, which is a wider set of countries than the EU and includes, eg, Norway and Turkey [9]. In addition, participation is possible from Cooperating State Israel, Near Neighbour Countries, and International Partner Countries. Hence, we have used a wider definition of Europe in this article, allowing also collaboration with and mutual learning from non-European countries.

ENCKEP started on September 1, 2016, bringing together policy makers, clinicians, and optimisation experts from 27 participating countries at the time of writing. The aims of ENCKEP are to 1. Exchange best practices and scientific state of the art with respect to national KEPs; 2. Develop a jointly-used common framework for data and optimisation; 3. Develop and test a prototype for transnational KEPs; 4. Stimulate European policy dialogue on this topic. In this study we report on research conducted to achieve the first aforementioned aim. We provide a comparative analysis of Europe’s current KEP practices and challenges.

**Materials and methods**

In order to systematically describe current KEP practices in Europe, a questionnaire has been developed to identify similarities and differences between countries, and future challenges. The questionnaire did not include individual patient or donor data and therefore no ethics board approval was needed.

The questionnaire was based on an earlier questionnaire that had been designed for the European Committee on Organ Transplantation within the Council of Europe (CD-P-TO) [8]. This original questionnaire was reviewed, amended, and restructured, following expert panel
discussion and involving representatives from the participating countries. These discussions were conducted partly at the first workshop of the COST Action in January 2017 [7], where most of the operating European KEPs were presented, and their main features were identified. The detailed written reports of the discussion were subsequently restructured into a new questionnaire by a smaller expert group, and then distributed for improvement suggestions to ENCKEP participants, resulting in a final commonly-approved questionnaire. The questionnaire was divided into sections focusing on:

- Short country description
- Numbers of registration and transplantation
- Activities
- Challenges and opportunities.

The questionnaires were sent to representatives of the ENCKEP countries in February 2017, who were asked to address all questions applicable to their country by March 2017. The data collected through the questionnaires were systematically presented and subsequently synthesised into conclusions and recommendations in a workshop in March 2017 [7], by representatives of the participating countries, as described in detail in the first ENCKEP Handbook [10]. Below, we first present the main results from the questionnaires as viewed and prioritised during these workshops. The reflections and interpretations formed during these workshops are included in the Discussion and Conclusions.

Results

In total, 17 of the 23 countries participating in ENCKEP completed the questionnaire. Countries were classified according to the level of development of their KEPs into 4 categories: 1. large, advanced programmes, 2. smaller operational programmes, 3. programmes in preparation, and 4. countries without KEPs (Figure 1).
Short country descriptions based on the responses from the questionnaire

The **Netherlands** has the highest number of living kidney donations in Europe per million population (pmp), and was the first country in Europe to establish a nationally coordinated KEP in 2004. The programme is coordinated by the Dutch Transplant Foundation in close collaboration with 8 transplant centers and a single Central Reference Laboratory for histocompatibility testing. From 2004 through 2016, the Dutch KEP has resulted in 284 transplants, facilitating exchanges up to 4 pairs [11],[12],[13],[14],[15],[16],[17],[18],[19],[20],[21],[22]. The **UK Living Kidney Sharing Schemes (UKLKSS)** includes all 4 nations (England, Wales, Scotland, Northern Ireland) and has been operational since 2007. It was made possible by the Human Tissue Acts 2004 (England, Northern Ireland, and Wales) and 2006 (Scotland). The programme is administered by NHS Blood and Transplant (NHSBT) and involves 23 transplant centers and 20 histocompatibility and immunogenetics (H&I) laboratories. It has become the largest operating KEP in Europe, with 250 recipient-donor pairs registered per matching run, and a total of 658 transplants reported [23], [24], [25]. The **Spanish** national programme was developed in 2009 by Organización Nacional de Transplantes (ONT) involving 25 of the 39 transplant centers and 18 H&I laboratories in the country. The Spanish programme is the second largest KEP in Europe after the UK with 110 donor-recipient pairs registered per matching run, and a total of 147 transplants reported.

As regards smaller programmes, the **Austrian** KEP started in 2013 with 4 participating transplant centers, coordinated by the Medical University of Vienna, with immunological testing on-site [26]. After conducting 11 transplants through 4 2-way exchanges and 1 3-way exchange between 2013-2016, Austria joined the Czech Republic to create 1 pool, and the first reported transnational exchange was performed in September 2016 [27]. The KEP in the **Czech Republic** started in 2011 and is organised by a single center, the Institute for Clinical
and Experimental Medicine (IKEM) Prague. Despite the limited pool size, 60 transplants were performed [28]. The reasons for this high number of transplants are: the flexibility in performing long exchanges nonsimultaneously (the Czech Republic has conducted 6- and 7-way exchanges), the fast laboratory testing that facilitates rematching in response to positive crossmatch tests, the involvement of altruistic donors and compatible pairs, and the possibility of performing ABOi and HLAi transplants after desensitisation within the KEP. The **Polish** programme started in 2015, organised by surgeons from the Department of General and Transplant Surgery, Medical University of Warsaw. Five transplants (through 1 2-way and 1 3-way exchange) had been performed in a single center (Warsaw) by 2016 and the first interhospital exchange was performed in 2017 between 2 centers.

The **Belgian** Living Donor Exchange Protocol was accepted in 2008 and the national KEP started in 2013, organised by the Kidney-Pancreas Committee and the Belgian Transplantation Society. The size of the pool is still limited, and 7 transplants have been reported through 2 2-way exchanges and 1 3-way exchange. The **French** KEP started in 2013, organised by the Agence de la Biomédecine. A total of 67 patients have been registered with a total of 10 transplants performed in 2-way exchanges. Altruistic donation is not legal in France, and exchanges involving more than 2 pairs are not yet allowed. The **Italian** KEP, run by the Italian National Transplant Centre (CNT), was established in 2006, but until 2014 only single-center exchanges were performed in the Pisa and Siena centers, achieving a total of 15 transplants. Since 2015 a further 16 transplants were conducted through long, but almost simultaneous, altruistic donor chains, involving up to 11 centers. The national KEP in **Portugal** started in 2010, administered by Instituto Português do Sangue e da Transplantação (IPST). Five transplant centers out of 8 and 3 H&I laboratories are participating. Fifty patients were registered and a total of 9 transplants were reported by the end of 2016.
In several countries the KEPs have just been created or are in preparation. **Sweden** started its national KEP in 2016. In 2017, the initiative was taken up by Scandiatransplant, under the name of ScandiaTransplant Kidney Exchange Program (STEP), involving **Sweden, Denmark** and **Norway**. A matching policy has been agreed and 2-way exchanges are currently allowed [29]. However, no transplants have been performed yet. In **Switzerland**, kidney exchange has been regulated by the Swiss Transplantation Law since 2007, but only a few ad hoc 2- and 3-way exchanges have been performed so far. In fact, in 1999, Europe’s first kidney exchange was carried out in Switzerland. However, there were legislative and organizational restrictions. Since these are solved, the Swiss KEP is expected to start in 2018 [30]. In **Greece**, a national KEP will be established by the Hellenic Transplant Organisation (EOM) in the near future, involving 5 kidney transplant centers. There is no national KEP in **Slovakia** yet, but there have been 7 ad hoc 2-way exchanges between 2005-2015. Among those, 6 were performed in single centers (within 3 of the 4 transplant centers in Slovakia) and 1 exchange was between 2 centers.

We have no information on other operating KEPs in Europe. However, **Romania** had a single center KEP in Cluj-Napoca from 2001 [31], [32]. Between 2001 and 2005, their medical team performed 56 transplants through 23 2-way exchanges, 2 3-way exchanges and 1 4-way exchange.

Regarding the countries that provided responses to our survey, but had no KEPs, **Finland** and **Iceland** are part of Scandiatransplant but they do not participate in STEP yet. Kidney exchange is not legally allowed in Finland; the Helsinki center performs all LDKT in the country. The LDKT programme in Iceland is supported by a visiting surgeon from the USA, and patients travel to Sweden for a deceased donor kidney transplant (DDKT). Recipient-donor pairs of **Ireland** can register through a UK transplant center for entry into UKLKSS, altogether 6 transplants have been performed by that route.
Statistics and comparisons

Regarding 12-month performance, the number of registrations and the number of transplantations conducted in 2015 can be seen in Figure 2.

The active KEPs in all 10 countries listed are organised centrally, although in the Czech Republic and Poland the programmes initially operated in the capitals, but they are now enlarging. Regarding legal restrictions, altruistic donation is not possible in France, Poland, Greece and Switzerland. In France and Portugal, only incompatible pairs can participate in the KEP. In France, only 2-way exchanges are possible. In principle, nonresident donor-recipient pairs can be involved in the majority of the KEPs except Portugal, where only resident recipients can join the KEP, and Belgium, where the recipient must be resident in a Eurotransplant country. Anonymity is a legal requirement in most countries and it is part of the protocol in all countries, except Poland. Compatible pairs can participate in KEPs in the advanced programmes. In Spain, both paediatric recipients and compatible pairs are prioritised within the KEP. Usually organs travel rather than donors, except in the Netherlands, Slovakia and Switzerland, where the donors travel according to the protocol. Simultaneous surgeries for exchanges are required everywhere by protocol, except in the Czech Republic and Poland due to large exchanges and lack of operating theatres, respectively.

In most countries, there are national guidelines for donors and recipients to enter the KEP. All the donors and recipients are fully assessed before inclusion in a KEP and in some countries special rules apply for clinically complex donors. Usually large countries have multiple laboratories to carry out crossmatch testing and smaller countries use 1 laboratory only. In all of the KEPs the exchanges/chains are identified after a virtual crossmatch and then these are confirmed in a laboratory crossmatch. Most countries have nationally agreed definitions of
HLA incompatibility and a commonly used Mean Fluorescence Intensity MFI threshold (between 2000-3000). Almost all countries consider results from historical samples as well, but the current ones are deemed most relevant. The practice regarding formal arrangements for reimbursing the expenses and loss of earnings of living donors varies between countries, but the countries with the most advanced KEPs have cost neutral reimbursement policies.

The algorithms which match recipients with donors mostly aim to maximise the number of transplants, in combination with a variety of other criteria. In many countries the optimisation considers the HLA-match between donors and recipients and/or blood type compatibility. Blood type identical transplants can be prioritised. Additionally, algorithms might look for smaller donor-recipient age-differences and travel distances (coming from the same region).

In the UK donor-donor age difference is used as a tie-breaker between possible matches. The sensitisation and the waiting time of the patient can also matter. Shorter exchange cycles are generally preferred in the solution.

We summarise these and other main features of the European KEPs in Table 1. We also included general data on the transplant activity of the countries covered in our survey in Table 2 and Table 3.

**Overview of activity beyond Europe**

There are several countries outside Europe where KEPs are operational, eg, in South Korea, USA, Canada, and Australia. For further information, we refer to 2 recent surveys [24,25] on KEPs around the world. Here, we include a description of the situation in the USA, and information on one of their nationwide KEPs, ie, the United Network for Organ Sharing (UNOS), which was established in 2010. UNOS is a partner organization in the ENCKEP COST Action.
In the USA, UNOS (which administers the Organ Procurement and Transplantation Network (OPTN)), the National Kidney Registry (NKR) and the Alliance for Paired Donation (APD) are the 3 KEPs operating nationwide. In addition, many regional and single-center programmes exist within approximately 250 living donor transplant centers. Seventy centers are actively participating with UNOS from among the 160 centers registered with this organization. Of note is that approximately 200 centers have conducted at least 1 transplant in an exchange through an internal hospital programme, a regional programme, or one of the national programmes in the USA. Some of the large transplant centers perform the majority of their exchanges in-house and report only their hard-to match patient-donor pairs to the national programmes. One of the organizational implications of this fragmented system is that the national KEPs do not wait to build up their pools, as is common practice in Europe.

UNOS conducts matching runs every week, and NKR and APD search for exchanges immediately after each registration. UNOS allows 2- and 3-way exchanges and 4-way chains for logistical reasons. Among the 173 transplants performed between 2010-2015, 52 were through 2-way exchanges 75 through 3-ways and 46 through altruistic chains. The high (90%) failure rate is the main issue in the US system. By the end of 2015, UNOS had 1628 registered patients and they identified 2246 matches in virtual crossmatch tests. Only 173 transplants proceeded, which is partly due to the practice of centers registering only hard-to-match patients and the lack of consistency in the HLA-lab testing.

**Challenges and opportunities**

The survey identified the following main challenges for countries that do not yet operate a KEP: (i) lack of knowledge about KEPs; (ii) lack of software tools; (iii) lack of a legal framework; and (iv) the small size of the country.
Descriptions of existing practices, as for instance provided above, as well as the ENCKEP COST Action itself, improve access to information and knowledge and serve to address the first challenge. Software to manage and optimise KEPs will also be investigated by ENCKEP, and future reports will enhance accessibility of existing technology for new countries.

The development of legislation to allow kidney exchanges (and its new modalities) is a task for policy makers and governments, in alignment with public opinion about living donor organ donation. Being well-informed about the operation and effects of existing KEPs across Europe may influence the beliefs and opinions of medical professionals, policy makers, the public and the government. Finally, as to the size of the country being a limitation, our results show that some medium-sized countries run effective KEPs or engage in international cooperation to this purpose.

Regarding the countries with operating KEPs, a key challenge reported by all countries is to maintain or increase the KEP pool size by encouraging new registrations. This holds particularly true for HLAi or ABOi pairs when routinely referred for desensitisation treatment (as is for example the case in France, Italy, and Sweden). The accumulation of highly HLA sensitised recipients in the pool is an issue for several countries, making it difficult to find suitable matches for immunologically complex recipients. As an example, we note that in Spain the proportion of highly sensitised (PRA>75%) patients has gradually increased from around 20% in 2010 to 50% in 2015.

There are essentially 3 categories of opportunities to improve the performance of the KEPs: (i) extending the national pools, (ii) allowing new modalities in the exchange, and (iii) increasing international cooperation.
(i) Extending national pools

- Reaching full coverage in the national KEPs through the participation of all the transplant centers.
- Inclusion of compatible pairs to achieve better HLA or age match for the recipients involved and generating more exchange opportunities for other recipients.
- Inclusion of HLA incompatible pairs in preference to antibody removal, and inclusion of ABO incompatible pairs to avoid the costs and higher risks associated with desensitisation programmes (at least by registering them for a number of runs in the KEP before choosing these alternative treatments).
- Inclusion of altruistic (unspecified) donors to trigger KEP chains, where the transplants can be nonsimultaneous and in the form of long or ‘never ending’ chains.
- Allowing multiple potential donors to register for 1 patient to improve the chances of identifying exchange cycles.

(ii) Allowing new modalities in the exchange

- Extending the length of simultaneous exchange cycles and nonsimultaneous chains.
- Considering HLAi and ABOi transplantations for hyperimmunised patients, in order for them to receive a kidney that is immunologically better than his/her original donor’s, with the help of desensitisation treatment.
- Improving the effectiveness of the selection of exchanges by fine-tuning the interaction between optimisation and the virtual and laboratory crossmatch tests. Flexibility with finding alternative exchanges in the light of a positive crossmatch is important in order to maximise transplants.
- Establishing an optimal run frequency. Depending upon the dynamics of the pool, finding the right frequency may further enhance the performance of the KEP.
(iii) Increasing international cooperation

There are a number of different models for current international collaborations and plans: some are led by an advanced KEP, whilst other countries are joining together their small pools in order to create larger pools. In the UK, patient-donor pairs from Ireland are welcome to participate, and 6 recipients have already received transplants. Spain, with the second largest KEP in Europe, has started cooperation with Italy and Portugal. The Netherlands helped to establish the Belgian KEP by sharing their software. France and Switzerland signed a KEPs convention in 2015, but to date no run has succeeded in identifying matched pairs. France is also in negotiation with Belgium. Austria and the Czech Republic have already joined their pools and performed their first transnational exchange in September 2016 [27], followed by a 3-way kidney exchange on 5th December 2017 involving 2 pairs in Prague and 1 in Vienna. Based on the Swedish initiative, Scandiatransplant has just started the coordination of a joint KEP involving Denmark, Norway, and Sweden. Eurotransplant is helping with the organization of the Belgian KEP and, theoretically, it is possible for a resident of a Eurotransplant country to join a KEP in another Eurotransplant country.

International Collaboration is an opportunity that in turn poses new challenges. It requires many legislative, medical, financial, and ethical issues to be resolved. As the example of deceased organ sharing networks (such as Eurotransplant and Scandiatransplant) shows, such international cooperation is feasible and can be beneficial for all stakeholders, and especially the highly sensitised patients.

Discussion

This study provides a comprehensive review of the state of the art of European KEPs in living donor kidney transplantation, identifying their key characteristics and their main challenges. Our findings clearly reveal the complexity of the (interorganizational) structures and
processes involved in KEPs. It appears that there is a considerable diversity among KEPs in participating countries, each having been developed in a different context and taking its own approach to address country-specific challenges. The most advanced programmes with a longer history have experience of how to advance by continuous review and improvement. The emerging/developing programmes can learn from these advancements as well as from other early stage programmes to develop a model that is suitable for their requirements. Recognising the differences in ethical viewpoints, legal frameworks, clinical practices, geography, population size, et cetera, it is clear that solutions that appear to work best in one country may be suboptimal in another and vice versa. One ‘model’ does not fit all.

The same differences between systems imply that collaboration in the form of transnational KEPs adds new complexities regarding ethical, legal, clinical, and financial frameworks of the countries involved. New principles, conditions and objectives are called for to ensure that collaboration appropriately benefits all populations, recipients and donors involved. Such collaboration may particularly benefit the growing number of highly sensitised patients who are hard to match nationally.

**Recommendations for national KEPs**

Based on our study we have identified the following key characteristics that define KEP effectiveness:

- a transparent, objective, and responsible donor selection system, including both physical and psychological screening;
- consistent and responsive systems and processes including matching software, immunological testing, organizational framework, and central coordination;
- clinical leadership to establish confidence in the KEP as the treatment of choice for immunologically complex recipients and compatible recipient-donor pairs seeking a
better age or HLA match and to ensure that recipients and donors are appropriately informed about their treatment options;

- recipient and donor awareness to inform their decision-making and encourage participation in the KEP;
- a centralised follow up system, to monitor the effectiveness of the programme in terms of the impact on the donor and recipient, and more generally in terms of overall outcomes;
- a culture of continuous improvement to develop the KEP in response to innovations in the field, clinician, and patient choice, and to actively manage potential risks (e.g., diminishing pool size, nonproceeding transplants, low uptake of the KEP).

**Future work**

Based on the trends observed in the development of European KEPs, we expect that new national programmes to be established and that countries with operating KEPs will advance their programmes according to the opportunities described above. In particular, we believe that more countries will permit altruistic donors to trigger long chains as part of the proposed exchanges, more countries will allow the participation of compatible donors in the programmes by providing quality guarantees for these patients, and desensitisation treatment will be better coordinated with the KEPs.

Besides the improvement of the national programmes, we expect the ongoing international collaborations to extend rapidly, partly facilitated by our ENCKEP COST Action, in particular for:

- sharing knowledge and expertise to support new, emerging, and developing programmes;
- effective cross-border collaborations to improve pool size and optimisation;
- advanced cross-border schemes to maximise options for immunologically complex recipients who remain unmatched within their own country KEPs.

Our ENCKEP network continues to conduct scientific research in an international and interdisciplinary collaboration on KEPs. The next steps are to identify best practices in modelling and optimisation aspects of the KEPs, and to address the ethical and legal challenges of (inter)national KEPs.

As effective KEPs ultimately benefit all patients, we hope that the presented detailed description of current KEP practices will guide advances in practice, foster international cooperation, and promote access to transplantation for the growing population of ESRD patients.
Acknowledgments

The authors would like to thank the reviewers for their valuable comments which have helped to improve the presentation of this paper. This article is based upon work from COST Action ENCKEP (CA15210), supported by COST (European Cooperation in Science and Technology); see www.cost.eu. COST financed our meetings (ie, the travel and accommodation costs of the participants), but it provided no other personal financial support to the authors. Personal acknowledgements: PB is supported by the Hungarian Academy of Sciences under research grants no. LP2016-3/2017 and KEP-6/2017. DM is supported by grant EP/P028306/1 from the Engineering and Physical Sciences Research Council. TA is funded by the Jan Wallander and Tom Hedelius Foundation (P2016-0126:1) and the Ragnar Söderberg Foundation (E8/13).
References


FIGURE LEGENDS

Figure 1: Development of KEPs by country

Figure 2: KEP activity: number of proceeding transplants and the number of new recipients registered in 2015 by country.
Figure 1
Figure 2

Number of recipients transplanted (blue) and newly registered (red) in KEP in 2015

Country

Number of recipients

0 50 100 150 200 250
Table 1: Summary of the characteristics of European kidney exchange programmes. The first 10 countries have operating programmes and the last 2 countries will start their KEPs in 2018.

<table>
<thead>
<tr>
<th></th>
<th>Austria</th>
<th>Belgium</th>
<th>Czech Republic</th>
<th>France</th>
<th>Italy</th>
<th>Netherlands</th>
<th>Poland</th>
<th>Portugal</th>
<th>Spain</th>
<th>UK</th>
<th>Sweden</th>
<th>Switzerland</th>
</tr>
</thead>
<tbody>
<tr>
<td>First exchange in KEP: 20XX</td>
<td>13</td>
<td>14</td>
<td>11</td>
<td>14</td>
<td>07</td>
<td>04</td>
<td>15</td>
<td>13</td>
<td>09</td>
<td>07</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Altruistic donor chains possible?</td>
<td>✓</td>
<td>×</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>✓</td>
<td>×</td>
</tr>
<tr>
<td>Compatible pairs/couples participate?</td>
<td>×</td>
<td>×</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>×</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Multiple donors register for one patient?</td>
<td>✓</td>
<td>×</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Incompatible transplants allowed within KEP?</td>
<td>✓</td>
<td>×</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Single lab carries out cross matching after virtual matching?</td>
<td>✓</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>✓</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
<td>×</td>
</tr>
<tr>
<td>Simultaneous surgery required for an exchange in KEP?</td>
<td>✓</td>
<td>✓</td>
<td>×</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>×</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Organs usually travel (O) or donors (D)?</td>
<td>D</td>
<td>O</td>
<td>-</td>
<td>O</td>
<td>O</td>
<td>D</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>O</td>
<td>D</td>
</tr>
<tr>
<td>Matching process every x months (NR=not regular)</td>
<td>NR</td>
<td>NR</td>
<td>3</td>
<td>3</td>
<td>NR</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td>na</td>
<td>3</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>----</td>
<td>----</td>
<td>---</td>
<td>---</td>
<td>----</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>----</td>
<td>---</td>
</tr>
<tr>
<td>Longest exchange already conducted</td>
<td>3</td>
<td>3</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Longest chain already conducted</td>
<td>na</td>
<td>na</td>
<td>6</td>
<td>na</td>
<td>6</td>
<td>3</td>
<td>na</td>
<td>na</td>
<td>6</td>
<td>3</td>
<td>na</td>
<td>na</td>
</tr>
</tbody>
</table>
Table 2: General information about the kidney transplantation activities of the 17 countries covered in the survey for 2016 from Newsletter Transplants [6], except the information denoted by * and ** that were not included in [6], so we took them from our survey provided for years 2015 (*) and 2016 (**), respectively, (here “nd” means we had no data provided from either of the 2 sources). Part a) countries with operating KEPs.

<table>
<thead>
<tr>
<th></th>
<th>Austria</th>
<th>Belgium</th>
<th>Czech Republic</th>
<th>France</th>
<th>Italy</th>
<th>Netherlands</th>
<th>Poland</th>
<th>Portugal</th>
<th>Spain</th>
<th>UK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population of country</td>
<td>8.6</td>
<td>11.4</td>
<td>10.5</td>
<td>64.7</td>
<td>59.8</td>
<td>17</td>
<td>38.6</td>
<td>10.3</td>
<td>46.1</td>
<td>65.1</td>
</tr>
<tr>
<td>(million)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total number of</td>
<td>432</td>
<td>520</td>
<td>458</td>
<td>3615</td>
<td>2076</td>
<td>426</td>
<td>1108</td>
<td>499</td>
<td>2997</td>
<td>3328</td>
</tr>
<tr>
<td>kidney transplants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td># of deceased kidney</td>
<td>365</td>
<td>453</td>
<td>412</td>
<td>3039</td>
<td>1796</td>
<td>565</td>
<td>1058</td>
<td>434</td>
<td>2654</td>
<td>2310</td>
</tr>
<tr>
<td>transplants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td># of living kidney</td>
<td>67</td>
<td>67</td>
<td>46</td>
<td>576</td>
<td>280</td>
<td>513</td>
<td>50</td>
<td>65</td>
<td>343</td>
<td>1018</td>
</tr>
<tr>
<td>transplants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td># of ABOi transplants</td>
<td>nd</td>
<td>nd</td>
<td>Nd</td>
<td>67*</td>
<td>53**</td>
<td>nd</td>
<td>1**</td>
<td>nd</td>
<td>33**</td>
<td>57*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td># of patients on</td>
<td>4451</td>
<td>nd</td>
<td>6668**</td>
<td>44419*</td>
<td>nd</td>
<td>6452*</td>
<td>21000</td>
<td>12458</td>
<td>27727</td>
<td>28000*</td>
</tr>
<tr>
<td>dialysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td># of active patients</td>
<td>587</td>
<td>813</td>
<td>506**</td>
<td>17698</td>
<td>6830</td>
<td>629</td>
<td>1069</td>
<td>2011</td>
<td>4309</td>
<td>5215</td>
</tr>
<tr>
<td>on waiting lists</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3: General information about the kidney transplantation activities of the 17 countries covered in the survey for 2016 from Newsletter Transplants [6], except the information denoted by * and ** that were not included in [6], so we took them from our survey provided for years 2015 (*) and 2016 (**), respectively, (here “nd” means we had no data provided from either of the 2 sources). Part b) countries with no operating KEP yet.

<table>
<thead>
<tr>
<th></th>
<th>Finland</th>
<th>Greece</th>
<th>Iceland</th>
<th>Ireland</th>
<th>Slovakia</th>
<th>Sweden</th>
<th>Switzerland</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population of country (million)</td>
<td>5.5</td>
<td>10.9</td>
<td>0.3</td>
<td>4.7</td>
<td>5.4</td>
<td>9.9</td>
<td>8.4</td>
</tr>
<tr>
<td>Total number of kidney transplants</td>
<td>262</td>
<td>124</td>
<td>5</td>
<td>172</td>
<td>143</td>
<td>425</td>
<td>305</td>
</tr>
<tr>
<td># of deceased kidney transplants</td>
<td>240</td>
<td>75</td>
<td>0</td>
<td>122</td>
<td>124</td>
<td>290</td>
<td>185</td>
</tr>
<tr>
<td># of living kidney transplants</td>
<td>22</td>
<td>49</td>
<td>5</td>
<td>50</td>
<td>19</td>
<td>135</td>
<td>120</td>
</tr>
<tr>
<td># of ABOi transplants</td>
<td>nd</td>
<td>5**</td>
<td>0**</td>
<td>nd</td>
<td>0**</td>
<td>nd</td>
<td>nd</td>
</tr>
<tr>
<td># of patients on dialysis</td>
<td>1836**</td>
<td>10548</td>
<td>68**</td>
<td>2075</td>
<td>3300</td>
<td>2914**</td>
<td>450</td>
</tr>
<tr>
<td># of active patients on waiting lists</td>
<td>310</td>
<td>1193</td>
<td>15**</td>
<td>481</td>
<td>278</td>
<td>446</td>
<td>531</td>
</tr>
</tbody>
</table>